# Faculty Position: Cancer In Vivo Gene Editing Investigators — Mayo Clinic

- Location: Jacksonville, FL
- Posted: Aug 12, 2026
- Status: open (checked Nov 22, 2026)
- Apply (employer's site): https://fa-euwp-saasfaprod1.fa.ocs.oraclecloud.com/hcmUI/CandidateExperience/en/sites/jobsearch/job/380252
- Employer record: https://visajobs.io/company/mayo-clinic.md

## Sponsorship history
- Tier: Employer history only
- With this exact title: 0

## Description
Up to two positions may be filled, with appointments based at either Mayo Clinic Florida or Mayo Clinic Rochester.
Position Description
The Mayo Clinic Comprehensive Cancer Center (MCCCC) enterprise sites in Jacksonville, Florida and Rochester, Minnesota invite applications for open-rank faculty positions for innovative and accomplished In Vivo Gene Editing Investigators (Physicians and Scientists) to expand in vivo gene editing efforts in the Mayo Clinic In Vivo Human Gene Editing Program (Precision Genomics: Interventional Therapeutics: PG:IT) and the Mayo Clinic Comprehensive Cancer Center’s Programs in Cell Therapy Discovery and Translational Science. These reflect Mayo Clinic and Mayo Clinic Comprehensive Cancer Center’s commitment to accelerating the next generation of engineered cell therapies and to advancing curative treatments for cancer and other diseases.
We seek exceptional investigators (scientists and physicians) with expertise in in vivo genome engineering and gene editing technologies (e.g., CRISPR/Cas systems, base editing, prime editing, epigenome editing, RNA editing, synthetic gene circuits, or related platforms) applied to human cells for ultimate therapeutic development and intervention. Successful candidates will have the opportunity to play a central role in advancing a rapidly growing, multidisciplinary cell therapy program focused on discovery science, translational innovation, and clinical impact.
A key component of this role will be close collaboration with established CAR-T and immune cell therapy scientists, leveraging advanced genetic editing strategies to enhance persistence, safety, resistance to exhaustion, efficacy, tumor microenvironment adaptation, and manufacturability. While the successful candidates will focus on applications in cancer, they will have the opportunity to work in oncology and non-oncology indications across the Mayo Clinic enterprise to develop novel gene-engineered approaches that expand the therapeutic reach of cellular therapies beyond cancer, including autoimmune, inflammatory, genetic, and other degenerative disorders.
Strategic Role and Leadership Expectations
The Gene Editing Scientist will:
Provide scientific expertise and have the opportunity for leadership roles in genome engineering strategies.
Partner closely with CAR-T investigators and translational immunotherapy teams to develop next-generation engineered immune cell platforms.
Develop innovative gene editing solutions to improve efficacy, durability, safety switches, multiplex editing strategies, and precision targeting in both malignant and non-malignant disease settings.
Build scalable and clinically translatable genetic engineering pipelines that accelerate progression from discovery to early-phase clinical trials.
Contribute to the strategic growth and national visibility of the Mayo Clinic PG:IT Program and Mayo Clinic Comprehensive Cancer Center’s Cell Therapy Programs.
Mentor trainees, junior faculty, and research staff within a collaborative and inclusive academic environment.
Participate in institutional initiatives aligned with Mayo Clinic and Mayo Clinic Comprehensive Cance Center’s vision to Cure, Connect, and Transform healthcare through transformative science.
The successful candidate will be a key driver in integrating advanced genome engineering technologies into existing and emerging cell therapy platforms, enabling novel approaches to immune cell engineering, stem cell modification, in vivo gene editing strategies, and precision genome correction programs.
Research Environment
Mayo Clinic and Mayo Clinic Comprehensive Cancer Center offer a highly collaborative and integrated academic medical center environment with expanding strengths in cell therapy, cancer immunotherapy, regenerative medicine, and translational science. Mayo Clinic and MCCCC have built a world-class research hub to transform cancer patient care through actionable target discovery and next-generation discovery and therapeutic platforms. These foundational platforms include Mayo Clinic Platform (www.mayoclinicplatform.org) which holds the fully digitized longitudinal patient records from 15M Mayo Clinic patients and 54M patients from across the nation and the globe with collaborating healthcare institutions, which facilitate research through development of longitudinal patient cohorts prior to and following disease diagnosis. Mayo Clinic has also developed very strong AI-driven discovery, translational, and clinical programs with exceptional “on premises” and cloud-based computational resources.
Faculty benefit from:
Established CAR-T and immune cell therapy programs with active clinical translation
State-of-the-art genome engineering and cell manufacturing infrastructure
Access to institutional core facilities including genomics, single-cell sequencing, proteomics, bioinformatics, and advanced imaging
Robust disease-focused centers supporting both oncology and non-oncology therapeutic innovation
Dedicated institutional support for regulatory strategy, clinical trial development, and commercialization pathways
Cross-campus collaboration opportunities with Mayo Clinic sites in Minnesota and Arizona.
The selected candidates will facilitate the development of forward-looking cell therapy strategy that integrates gene editing platforms with clinical translation infrastructure.
Why Choose Mayo Clinic Comprehensive Cancer Center?
With 440 members and >1500 aligned cancer physicians working in six Cancer Research Programs (Cancer Prevention, Survivorship & Control; Cancer Risk Assessment, Early Detection & Interception; Cancer Genomics, Signaling, & Metastasis; Cancer Immunology & Immunotherapeutics; Novel Therapeutics & Therapeutic Modalities; Advanced Clinical Trials and Translational Sciences) and 15 Disease Groups focused on clinical trials, MCCCC is a global leader and represents the pinnacle of cancer care, research and education and training. Every year, across its three enterprise 

> History, not a promise: past H-1B filings do not mean an employer will sponsor you or a given role. Data: U.S. DOL OFLC LCA disclosure (FY2024–FY2026 for role counts, certified LCAs) and the USCIS H-1B Employer Data Hub. Not legal advice. Methodology: https://visajobs.io/methodology
